Peringatan Keamanan

In rats, omega-3-acid ethyl esters are not mutagenic or clastogenic and do not lead to impairment of fertilityFDA Label.

Safety in human pregnancy have not been performed, however an embryocidal effect was seen in rats force fed 7 times the maximum recommended human doseFDA Label. The risk and benefit of treatment during pregnancy should be weighed before deciding on treatmentFDA Label.

Animal studies in lactating rats have shown excretion of omega-3-acid ethyl esters at concentrations 6 to 14 times higher than in the serum of the mother, however the effects of this excretion on a mother or child have not been establishedFDA Label.

Safety and effectiveness in pediatric patients has not been establishedFDA Label.

There appear to be no differences in the safety and efficacy in patients above or below 60 years of age based on limited dataFDA Label.

Omega-3-acid ethyl esters

DB09539

small molecule approved investigational

Deskripsi

Omega-3-acid ethyl esters are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (? 500 mg/dL) hypertriglyceridemiaFDA LabelA176687. Omega-3-acid ethyl esters are currently marketed in the US, EU, and many other regions under the brand name LovazaFDA LabelL5849.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 79 hours ± 47 hours[A18890].
Volume Distribusi 82 ± 56L[A18890]
Klirens (Clearance) 757 mL/h ± 283mL/h[A18890].

Absorpsi

Omega-3-acid ethyl esters are rapidly hydrolysed to free fatty acids in the intestinal lumen which then become incorporated into phospholipids, cholesterol, and triglycerides so determination of bioavailability by serum concentration is not possibleL5852,A176708.

Metabolisme

Omega-3-acid ethyl esters are hydrolysed to free fatty acids in the intestinal lumen by pancreatic lipaseA176708. Once in enterocytes, the free fatty acids are packaged in chylomicrons which are released from cells into the circulationA176708. Fatty acids then enter the liver where they can be incorporated into liver stores, incorporated into lipoprotein phospholipids, or oxidised for energyL5852.

Rute Eliminasi

Includes oxidative catabolism to carbon dioxide and water

Interaksi Makanan

2 Data
  • 1. Take with a full glass of water.
  • 2. Take with food. Take with food to reduce gastrointestinal disturbance.

Interaksi Obat

117 Data
Ibrutinib Omega-3-acid ethyl esters may increase the antiplatelet activities of Ibrutinib.
Lepirudin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Lepirudin.
Bivalirudin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Bivalirudin.
Alteplase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Alteplase.
Urokinase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Urokinase.
Reteplase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Reteplase.
Anistreplase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Anistreplase.
Tenecteplase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tenecteplase.
Abciximab The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Abciximab.
Drotrecogin alfa The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Drotrecogin alfa.
Streptokinase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Streptokinase.
Dicoumarol The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dicoumarol.
Argatroban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Argatroban.
Ardeparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ardeparin.
Phenindione The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Phenindione.
Fondaparinux The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Fondaparinux.
Warfarin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Warfarin.
Pentosan polysulfate The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Pentosan polysulfate.
Phenprocoumon The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Phenprocoumon.
Dipyridamole The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dipyridamole.
Heparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Heparin.
Enoxaparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Enoxaparin.
Epoprostenol The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Epoprostenol.
Acenocoumarol The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Acenocoumarol.
4-hydroxycoumarin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with 4-hydroxycoumarin.
Coumarin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Coumarin.
Ximelagatran The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ximelagatran.
Desmoteplase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Desmoteplase.
Defibrotide The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Defibrotide.
Ancrod The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ancrod.
Beraprost The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Beraprost.
Prasugrel The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Prasugrel.
Rivaroxaban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Rivaroxaban.
Sulodexide The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sulodexide.
Semuloparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Semuloparin.
Idraparinux The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Idraparinux.
Cangrelor The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Cangrelor.
Astaxanthin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Astaxanthin.
Apixaban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Apixaban.
Otamixaban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Otamixaban.
Amediplase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Amediplase.
Dabigatran etexilate The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dabigatran etexilate.
Danaparoid The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Danaparoid.
Dalteparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dalteparin.
Tinzaparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tinzaparin.
(R)-warfarin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with (R)-warfarin.
Ethyl biscoumacetate The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ethyl biscoumacetate.
Nadroparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Nadroparin.
Triflusal The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Triflusal.
Ticagrelor The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ticagrelor.
Ditazole The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ditazole.
Vorapaxar The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Vorapaxar.
Edoxaban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Edoxaban.
Sodium citrate The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sodium citrate.
Dextran The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dextran.
Bemiparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Bemiparin.
Parnaparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Parnaparin.
Desirudin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Desirudin.
Antithrombin Alfa The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Antithrombin Alfa.
Protein C The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Protein C.
Antithrombin III human The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Antithrombin III human.
Letaxaban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Letaxaban.
Darexaban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Darexaban.
Betrixaban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Betrixaban.
Nafamostat The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Nafamostat.
Monteplase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Monteplase.
Gabexate The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Gabexate.
Fluindione The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Fluindione.
Protein S human The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Protein S human.
Brinase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Brinase.
Clorindione The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Clorindione.
Diphenadione The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Diphenadione.
Tioclomarol The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tioclomarol.
Melagatran The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Melagatran.
Saruplase The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Saruplase.
(S)-Warfarin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with (S)-Warfarin.
Tocopherylquinone The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tocopherylquinone.
Dabigatran The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dabigatran.
Troxerutin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Troxerutin.
Edetic acid The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Edetic acid.
Reviparin The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Reviparin.
Dermatan sulfate The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dermatan sulfate.
SR-123781A The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with SR-123781A.
Eptifibatide The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Eptifibatide.
Ticlopidine The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ticlopidine.
Clopidogrel The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Clopidogrel.
Tirofiban The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tirofiban.
Pentoxifylline The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Pentoxifylline.
Sulfinpyrazone The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Sulfinpyrazone.
Cilostazol The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Cilostazol.
Ridogrel The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ridogrel.
Resveratrol The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Resveratrol.
Nimesulide The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Nimesulide.
Tesmilifene The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tesmilifene.
Ibudilast The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Ibudilast.
Andrographolide The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Andrographolide.
Caplacizumab The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Caplacizumab.
Tranilast The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Tranilast.
Icosapent ethyl The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Icosapent ethyl.
Trapidil The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Trapidil.

Target Protein

Sterol regulatory element-binding protein 1 SREBF1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 26097787
    Braeckman RA, Stirtan WG, Soni PN: Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy Subjects. Clin Pharmacol Drug Dev. 2014 Mar;3(2):101-108. Epub 2013 Oct 22.
  • PMID: -
    Koski R: Omega-3-acid Ethyl Esters (Lovaza) For Severe Hypertriglyceridemia Pharmacy and Therapeutics. 2008 May;33(5):271-303.
  • PMID: 24184945
    Davidson MH: Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013 Dec;24(6):467-74. doi: 10.1097/MOL.0000000000000019.

Contoh Produk & Brand

Produk: 83 • International brands: 0
Produk
  • Concept DHA
    Capsule, liquid filled • - • Oral • US
  • Divista
    Capsule • - • Oral • US
  • Lovaza
    Capsule, liquid filled • 1 g/1 • Oral • US • Approved
  • Lovaza
    Capsule, liquid filled • 1 g/1 • Oral • US • Approved
  • Lovaza
    Capsule, liquid filled • 900 mg/1 • Oral • US • Approved
  • Lovaza
    Capsule, liquid filled • 900 mg/1 • Oral • US • Approved
  • Lovaza
    Capsule, liquid filled • 900 mg/1 • Oral • US • Approved
  • Lovaza
    Capsule, liquid filled • 900 mg/1 • Oral • US • Approved
Menampilkan 8 dari 83 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul